CRISPR Therapeutics AG

CRISPR Therapeutics AG a gene editing company focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas including hemoglobinopathies oncology regenerative medicine and rare diseases. The company's lead product candidate is CTX001 an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110 a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120 a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition the company develops VCTX210 a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211 an investigational allogeneic gene-edited stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC Vertex Pharmaceuticals Incorporated ViaCyte Inc. Nkarta Inc. and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug Switzerland.